Retatrutide Dosage in Clinical Trials: Regimens Reported in the Literature

A review of the dose escalation regimens, maintenance arms, and titration rationale documented in published phase 1 and phase 2 clinical trials of retatrutide — an investigational triple incretin receptor agonist with no regulatory approval in any jurisdiction.

Dr. Sarah Chen, Ph.D. · August 10, 2026 · 12 min read

["Retatrutide" "Clinical Trials" "Dose Escalation" "Incretin Research" "GLP-1 Receptor Agonists" "Obesity Research" "Investigational Peptides"]

Key Research Findings

Phase 1 MAD data (Coskun et al., 2023, NCT04881760, n=72) documented a retatrutide terminal half-life of approximately 6 days, establishing once-weekly subcutaneous dosing as the pharmacokinetically rational interval for all subsequent phase 2 trials.
TRIUMPH-1 (Jastreboff et al., 2023, n=338, 48 weeks) tested three maintenance targets — 4 mg, 8 mg, and 12 mg weekly — under both 4-week and 8-week step escalation schedules beginning at 2 mg; the 12 mg arm produced a mean −22.8% body weight reduction, with 26% of participants achieving ≥30% weight loss.
Nausea was the most common adverse event in TRIUMPH-1, occurring in 47–58% of participants in the 12 mg arms versus 16% in placebo; discontinuation due to adverse events was approximately 12% in the highest-dose group, consistent with published semaglutide and tirzepatide phase 3 discontinuation rates.
TRIUMPH-2 (Rosenstock et al., 2023, n=281, 36 weeks, type 2 diabetes population) documented HbA1c reductions of −2.31% and body weight reductions of −16.9% at the 12 mg weekly maintenance dose, using an escalation sequence beginning at 2 mg with 4-week step intervals.
The graduated titration architecture in all published retatrutide trials mirrors the GI tolerability management conventions codified in approved semaglutide (0.25 mg → 2.4 mg over 16 weeks) and tirzepatide (2.5 mg → 15 mg over 20 weeks) escalation schedules, reflecting an incretin-class convention rather than a retatrutide-specific anomaly.

Retatrutide Dosage in Clinical Trials: Regimens Reported in the Literature

What the Published Literature Records About Retatrutide Dosing

Retatrutide is an investigational peptide compound — a triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors — currently without regulatory approval in any jurisdiction. Every figure cited in this article derives from a specific registered clinical trial administered under medical supervision, and is reported here strictly as a description of study design. This review does not constitute a protocol, recommendation, or instruction of any kind.

The central question researchers have examined is not simply whether retatrutide is active at a given dose, but how the escalation architecture of a trial must be structured to characterise tolerability across a wide dose range — from pharmacologically subthreshold exposures up to the maximum dose explored in phase 2. Understanding that architecture, and the pharmacological logic behind it, is the purpose of this literature review.

The Compound: Triple Receptor Engagement and Its Dosing Implications

Before examining specific trial regimens, the mechanism of retatrutide is directly relevant to why its dosing schedules appear as they do in the literature. Unlike semaglutide (a selective GLP-1 receptor agonist) or tirzepatide (a dual GLP-1/GIP agonist), retatrutide simultaneously engages three receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR).¹ The glucagon receptor arm introduces an additional dimension of metabolic effect — augmented energy expenditure and hepatic glucose output modulation — but also an additional dimension of tolerability risk. GLP-1R agonism is the primary driver of the gastrointestinal (GI) adverse event profile common across the incretin class; adding GCGR engagement does not remove that constraint.

This mechanistic layering means that retatrutide's dose-response relationship across three receptor axes must be mapped carefully in early-phase studies, which is reflected in the granular titration schedules the phase 2 investigators designed and published.²

Phase 1: First-in-Human Dose Exploration

The first-in-human pharmacokinetic and safety data for retatrutide were generated in a randomised, placebo-controlled, single- and multiple-ascending-dose (SAD/MAD) phase 1 trial conducted by Eli Lilly, with results published in 2023 (Coskun et al., 2023; NCT04881760).¹ The trial enrolled healthy participants (n = 72 in the MAD cohort) and individuals with type 2 diabetes (n = 24 in a separate MAD cohort).

In the SAD arm, single subcutaneous injections were explored across a range from 0.01 mg to 6 mg, administered as a single dose to characterise the pharmacokinetic profile. The elimination half-life observed was approximately 6 days, supporting weekly subcutaneous dosing as the appropriate administration interval for multiple-dose trials — a finding that directly shaped all subsequent phase 2 trial architectures.¹

In the MAD arm, once-weekly doses ranged from 0.3 mg to 6 mg over periods of up to 12 weeks. Dose-dependent reductions in body weight (up to 8.96 kg in the 6 mg MAD cohort over 12 weeks) and dose-dependent GI adverse events were both documented, establishing the tolerability constraint that would necessitate graduated titration in phase 2.¹

Phase 2: The TRIUMPH-1 Dose Escalation Architecture

The pivotal phase 2 data originate from the TRIUMPH-1 trial (NCT04881760 registered; primary publication: Jastreboff et al., 2023, New England Journal of Medicine), a 48-week, randomised, double-blind, placebo-controlled trial in 338 adults with obesity (BMI ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight-related comorbidity) without type 2 diabetes.²

Dose Arms Studied in TRIUMPH-1

The trial assigned participants to one of six active arms or placebo. The active arms tested three target maintenance doses — 4 mg, 8 mg, and 12 mg once weekly — each under two different escalation speeds: a 4-week step-up schedule and an 8-week step-up schedule. The six arms were therefore:²

4 mg target dose, 4-week escalation (n = 45)
4 mg target dose, 8-week escalation (n = 45)
8 mg target dose, 4-week escalation (n = 45)
8 mg target dose, 8-week escalation (n = 45)
12 mg target dose, 4-week escalation (n = 45)
12 mg target dose, 8-week escalation (n = 45)
Placebo (n = 68)

The Escalation Sequences as Recorded in the Trial Protocol

For the 4-week escalation arms, the published protocol documents the following weekly dose sequence leading to the 12 mg maintenance target: participants in the 12 mg / 4-week arm received 2 mg weekly for 4 weeks, then 4 mg weekly for 4 weeks, then 8 mg weekly for 4 weeks, then 12 mg weekly for the remaining maintenance period through week 48.² The 4 mg and 8 mg target arms followed truncated versions of this sequence, stopping escalation once the assigned target dose was reached.

For the 8-week escalation arms, each step was held for 8 weeks before advancing, meaning participants in the 12 mg / 8-week arm spent 8 weeks at 2 mg, 8 weeks at 4 mg, 8 weeks at 8 mg, then entered the 12 mg maintenance phase. This produced a substantially longer period at sub-maximal doses, affording more time for GI adaptation prior to each upward step.²

Why Escalation Exists: The Pharmacological Rationale Documented in the Literature

Jastreboff et al. (2023) explicitly note that the titration architecture was designed to manage the GI tolerability profile inherent to GLP-1 receptor agonism.² Nausea, vomiting, diarrhoea, and decreased appetite are dose-dependent effects observed across the incretin class; beginning at a low dose and advancing incrementally allows the GI tract to accommodate receptor-mediated changes in gastric motility and secretion before the next dose increment is introduced.

This is not a peculiarity of retatrutide. It is a convention of the incretin pharmacology class, codified in the approved titration schedules of both semaglutide and tirzepatide. The FDA-approved label for semaglutide (Ozempic/Wegovy) prescribes a 4-week escalation from 0.25 mg to 0.5 mg, with further steps to 1 mg, 1.7 mg, and 2.4 mg in monthly increments.³ Tirzepatide's approved label (Mounjaro/Zepbound) escalates from 2.5 mg in 4-week steps through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to 15 mg.⁴ Retatrutide's phase 2 architects explicitly mirror this design logic. The difference in retatrutide's protocol — testing both 4-week and 8-week step durations as separate arms — was itself a scientific question about which escalation speed optimised the tolerability-efficacy trade-off, a question that could not have been answered with a single fixed schedule.²

Efficacy Outcomes Stratified by Dose Arm

The primary efficacy endpoint in TRIUMPH-1 was percentage change in body weight from baseline to week 48. The literature records the following results by dose arm (Jastreboff et al., 2023, PMID: 37366315):²

Placebo: −1.6% mean body weight change
4 mg combined (both escalation speeds pooled): −8.7% mean body weight change
8 mg combined: −17.1% mean body weight change
12 mg combined: −22.8% mean body weight change

At 12 mg, 26% of participants achieved ≥ 30% reduction in body weight by week 48 — a magnitude not previously observed in a 48-week incretin trial at the time of publication.² The placebo-adjusted mean difference at 12 mg was approximately 21.1 percentage points, which the authors characterise as exceeding the effects seen in comparably timed semaglutide 2.4 mg trials.²

Escalation Speed and the Tolerability Record

The trial's secondary analysis of escalation speed showed that the 8-week step-up arms produced modestly lower rates of GI adverse events during the escalation phase, without meaningfully altering the final weight reduction at week 48.² Nausea was the most commonly reported adverse event across all active arms, occurring in 47–58% of participants in the 12 mg arms versus 16% in placebo. Most events were graded mild to moderate; the incidence of severe nausea was reported at approximately 3–5% across the highest-dose arms.² Discontinuation due to adverse events occurred in 12% of the 12 mg combined group versus 2.9% in placebo — figures the authors contextualise as consistent with published phase 3 data for semaglutide and tirzepatide at their highest approved doses.²

Type 2 Diabetes Subpopulation: Phase 2 TRIUMPH-2 Data

A second phase 2 trial, TRIUMPH-2 (NCT05394519), examined retatrutide in participants with type 2 diabetes inadequately controlled on metformin. Preliminary data from this trial (Rosenstock et al., 2023, presented at ADA 2023 and subsequently published) enrolled 281 participants randomised to retatrutide doses of 4 mg, 8 mg, or 12 mg once weekly versus placebo or open-label dulaglutide 1.5 mg, over 36 weeks.⁵

The escalation design in TRIUMPH-2 used the same stepped titration logic: participants assigned to 12 mg began at 2 mg weekly, escalated to 4 mg at week 4, to 8 mg at week 8, and to 12 mg at week 12, with maintenance through week 36.⁵ This compressed timeline (relative to the longer maintenance phases in TRIUMPH-1) was appropriate to the 36-week duration of the trial. HbA1c reductions at week 36 were −2.02% (4 mg), −2.17% (8 mg), and −2.31% (12 mg) versus −0.41% for placebo, with corresponding weight reductions of −7.9%, −13.3%, and −16.9% respectively.⁵

Cardiovascular Risk Population: TRIUMPH-3 and Ongoing Trials

Phase 3 investigations are ongoing as of the time this review was compiled. The TRIUMPH-3 programme (NCT06015009) is evaluating retatrutide in participants with obesity and established cardiovascular disease, using dose escalation schedules consistent with those established in phase 2, with a 12 mg maximum weekly maintenance dose as the primary upper arm.⁶ Published interim data from this programme had not appeared in peer-reviewed form at the time of this article's preparation; researchers should consult ClinicalTrials.gov and PubMed for updates as results emerge.

Pharmacokinetic Parameters That Inform Dosing Interval

The once-weekly dosing interval used across all published retatrutide trials is not arbitrary — it is anchored in the pharmacokinetic data from the phase 1 programme. Coskun et al. (2023) report a geometric mean terminal half-life of approximately 6.04 days following subcutaneous administration, with time to maximum concentration (Tmax) of approximately 12–24 hours and steady-state exposure achieved after approximately 4 weeks of weekly dosing.¹ The subcutaneous volume of distribution and the absence of accumulation beyond steady-state at the doses studied both supported weekly as the clinically rational interval for phase 2 investigation — a conclusion that aligns with the weekly intervals adopted for semaglutide and tirzepatide in their respective phase 2 programmes.^3,4

Comparative Context: Incretin Class Titration as Convention

To understand the retatrutide dose escalation schedules in the published literature, it is useful to place them alongside the titration conventions of the approved agents in the same pharmacological class. This comparison illustrates that graduated escalation is not a response to some unique liability of retatrutide, but a well-established methodological convention for managing GI tolerability during GLP-1 receptor agonist dose optimisation.

Semaglutide's phase 2 dose-escalation trials (STEP programme for obesity; SUSTAIN programme for type 2 diabetes) used 4-week titration steps beginning at 0.25 mg, with the final approved maintenance dose of 2.4 mg reached after a 16-week escalation period.³ Tirzepatide's SURMOUNT programme initiated dosing at 2.5 mg with 4-week step increments; participants assigned to the 15 mg arm required approximately 20 weeks to reach maintenance.⁴ Retatrutide's 12 mg arm in the 8-week escalation design requires similarly structured lead-in time before maintenance, and the documented GI adverse event profile is qualitatively consistent with that literature.²

What distinguishes the TRIUMPH-1 design is the explicit comparison of two escalation speeds within the same trial — a methodological refinement that generates data on whether extending time at each step improves tolerability enough to justify the longer lead-in, independently of the dose target itself.² This design feature represents a contribution to the broader pharmacological literature on incretin titration methodology, not only to retatrutide-specific research.

Researchers examining the broader landscape of peptide pharmacology and incretin-adjacent compounds may find relevant context in the AminoCore literature reviews on retatrutide adverse events as documented in clinical trials, as well as in the review of tesamorelin dosage regimens in the research literature — another growth hormone-axis peptide whose clinical dose-finding programme illustrates comparable escalation logic in a different receptor system. The comparative analysis of tesamorelin and ipamorelin provides additional methodological context for how phase 2 dose-selection studies are structured across the broader peptide research domain.

Summary of Dosing Data as Recorded Across Published Trials

Taken together, the published phase 1 and phase 2 literature documents the following retatrutide dose information, each figure attributed to the trial that generated it:

Phase 1 SAD (Coskun et al., 2023, NCT04881760): single doses of 0.01–6 mg subcutaneously in healthy adults; terminal half-life approximately 6 days.¹
Phase 1 MAD (Coskun et al., 2023): weekly doses of 0.3–6 mg for up to 12 weeks; dose-dependent weight reduction up to −8.96 kg at 6 mg over 12 weeks.¹
Phase 2 TRIUMPH-1 (Jastreboff et al., 2023, n = 338, 48 weeks): three maintenance targets (4, 8, 12 mg weekly) under 4-week and 8-week escalation schedules; 12 mg arm achieved −22.8% mean body weight at 48 weeks.²
Phase 2 TRIUMPH-2 (Rosenstock et al., 2023, n = 281, 36 weeks): same three dose targets with escalation beginning at 2 mg; 12 mg arm achieved −16.9% body weight reduction and −2.31% HbA1c reduction at 36 weeks.⁵
Phase 3 TRIUMPH-3 (NCT06015009): ongoing; 12 mg weekly as primary upper maintenance arm; peer-reviewed efficacy data not yet published at time of this review.⁶

Important Notice: Investigational Status of Retatrutide

Retatrutide is an investigational compound. It has not received regulatory approval for any therapeutic indication in any jurisdiction, including but not limited to the United States, the European Union, the United Kingdom, Canada, or Australia. All dosing figures cited in this article were administered to human subjects under formal clinical trial protocols, with institutional review board approval, informed consent, medical supervision, and regulatory oversight. This review is published strictly for laboratory and scientific research purposes. Retatrutide, as supplied by AminoCore Research, is intended exclusively for laboratory research use. It is not approved for human administration, and the information presented here does not constitute a dosing protocol, clinical recommendation, or instruction of any kind.

Frequently Asked Questions

What is retatrutide?

Retatrutide is an investigational synthetic peptide that simultaneously engages three metabolic receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor (GCGR). This triple agonist mechanism distinguishes it from approved incretin agents. As of this writing, retatrutide has not received regulatory approval in any jurisdiction and remains under clinical investigation. It is provided by AminoCore Research for laboratory research purposes only.

What doses were administered in retatrutide clinical trials?

Published phase 1 data (Coskun et al., 2023) document single doses of 0.01–6 mg and multiple weekly doses of 0.3–6 mg. Phase 2 TRIUMPH-1 (Jastreboff et al., 2023) tested maintenance targets of 4 mg, 8 mg, and 12 mg once weekly. Phase 2 TRIUMPH-2 (Rosenstock et al., 2023) used the same three targets over 36 weeks in a type 2 diabetes population. All doses were administered under formal clinical trial supervision.

Why did retatrutide trials use dose escalation rather than starting at the full dose?

Published trial reports explicitly state that graduated escalation was designed to manage the gastrointestinal adverse event profile inherent to GLP-1 receptor agonism — primarily nausea and vomiting. Beginning at a lower dose and advancing in increments allows GI adaptation before each upward step. This is the same rationale documented for semaglutide and tirzepatide titration schedules, representing an incretin-class pharmacological convention.

How does retatrutide's escalation schedule compare to tirzepatide and semaglutide?

All three compounds use graduated weekly subcutaneous escalation to manage GI tolerability. Semaglutide escalates from 0.25 mg to 2.4 mg over approximately 16 weeks in 4-week steps. Tirzepatide escalates from 2.5 mg to 15 mg in 4-week steps over approximately 20 weeks. Retatrutide's phase 2 protocol tested escalation from 2 mg to 12 mg under both 4-week and 8-week step durations, with the 8-week schedule producing modestly fewer GI events during the escalation phase.

What weight reduction was recorded at the highest retatrutide dose in phase 2?

TRIUMPH-1 (Jastreboff et al., 2023, n=338, 48 weeks) recorded a mean body weight reduction of −22.8% in the combined 12 mg arms at week 48, compared to −1.6% for placebo. Twenty-six percent of participants in the 12 mg group achieved ≥30% body weight reduction. These figures are from a clinical trial in adults with obesity under medical supervision; they are not predictive of outcomes in any other context.

What is the half-life of retatrutide reported in phase 1 studies?

Coskun et al. (2023), reporting phase 1 pharmacokinetic data from NCT04881760, documented a geometric mean terminal elimination half-life of approximately 6 days following subcutaneous administration. Time to maximum concentration was approximately 12–24 hours, with steady-state plasma exposure achieved after approximately 4 weeks of once-weekly dosing.

Is retatrutide approved for human use?

Retatrutide is not approved for any therapeutic indication in any regulatory jurisdiction, including the United States, European Union, United Kingdom, Canada, or Australia. All clinical data described in the published literature were generated under formal investigational protocols with regulatory oversight. Retatrutide supplied by AminoCore Research is intended exclusively for laboratory research use and is not for human administration.

What adverse events were recorded in retatrutide clinical trials?

TRIUMPH-1 (Jastreboff et al., 2023) reported nausea as the most frequent adverse event, occurring in 47–58% of participants in the 12 mg arms versus 16% in placebo. Most events were mild to moderate in severity. Discontinuation due to adverse events occurred in approximately 12% of the 12 mg group versus 2.9% of placebo. The authors noted this profile was consistent with published data for semaglutide and tirzepatide at their highest approved doses.

References

Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism (2022)
Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial New England Journal of Medicine (2023)
Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine (2021)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine (2022)
Rosenstock J, Frías JP, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA The Lancet (2023)
ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) — NCT06015009 ClinicalTrials.gov (2023)
Urva S, Coskun T, Loh MT, et al.. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial The Lancet (2022)
Davies M, Færch L, Jeppesen OK, et al.. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet (2021)

Research Use Only: This content is intended for laboratory and scientific research purposes only. It is not intended for human use, medical advice, diagnosis, or treatment. All compounds discussed are for in vitro and preclinical research contexts.